Back to Archived News
iCAD Granted U.S. Patent on CAD Lesion Metrics That Enhance Clinical Information for Image Analysis Solutions
Monday, March 08, 2010
Nashua, NH -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces that the United States Patent and Trademark Office recently granted the company Patent Number 7,660,448. This patent covers future iterations of iCAD’s SecondLook® Digital Computer-Aided Detection (CAD) solution with potential application to the company’s other image analysis solutions. iCAD has developed and now patented this technology, which incorporates CAD lesion metrics to provide clinicians with enhanced clinical information.
"iCAD’s R&D teams are continually striving to provide the most sophisticated image analysis solutions that incorporate feedback from our global customer base of radiology professionals," said Ken Ferry, President and CEO of iCAD. "Advancements covered by this new patent will incorporate CAD lesion metrics that can provide clinicians with insight into the system’s decision making process."
iCAD was also recently granted a U.S. patent for a Computed Tomography (CT) image analysis software development. This patent was developed to improve the way CT image analysis solutions can assess data three-dimensionally.
These patents are included among iCAD’s broad patent portfolio that is based on years of research and development on its image analysis solutions for existing and new product applications. iCAD currently has 27 granted U.S. patents and 15 U.S. patent applications pending.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, more than 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast and prostate, and in the future colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
Back to Archived News